Genmab A/S is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in 1253 Copenhagen K, DK. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $3.7 billion and a profit of $963 million (its filed statements).
Product businessPharmaceutical Preparations1253 Copenhagen K, DKfilings since 20087 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.8 out of ten, 7 of 9 metrics filed and 2 estimated: past 7.6 out of ten, present 6.9 out of ten, future 5.8 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 8.6 out of ten. +24.7% a year over 3 filed years; profitable in 3 of 3. 86th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.9 out of ten. Share count shrank 0.2% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases. 49th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 6.8 out of ten. ROE 16%: 16¢ of profit per shareholder dollar. Leverage 55%: owes 55¢ per asset dollar. 69th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 8.2 out of ten. top 18% of 314 in its family; net margin 25.9%. 82nd percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 371 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 5.8 out of ten. top 42% of 272 in its family for room to expand. 58th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.2 out of ten. top 38% of 307 in its family for growth drivers. 62nd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 20-F filed 2026-02-17 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-10-07. Filings on record since 2008. Read from EDGAR 2026-10-12.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.